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While the molecular functions of miR‑200 family have been deeply investigated, a role for these 
miRNAs as breast cancer biomarkers remains largely unexplored. In the attempt to clarify this, we 
profiled the miR‑200 family members expression in a large cohort of breast cancer cases with a long 
follow‑up (H‑CSS cohort) and in TCGA‑BRCA cohort. Overall, miR‑200 family was found upregulated 
in breast tumors with respect to normal breast tissues while downregulated in more aggressive breast 
cancer molecular subtypes (i.e. Luminal B, HER2 and triple negative), consistently with their function 
as repressors of the epithelial‑to‑mesenchymal transition (EMT). In particular miR‑141‑3p was found 
differentially expressed in breast cancer molecular subtypes in both H‑CSS and TCGA‑BRCA cohorts, 
and the combined analysis of all miR‑200 family members demonstrated a slight predictive accuracy 
on H‑CSS cancer specific survival at 12 years (survival c‑statistic: 0.646; 95%CI 0.538–0.754).
With five highly conserved miRNAs (i.e. miR-141, miR-200a, miR-200b, miR-200c and miR-429), the miR-200 
family is one of the most frequent groups of miRNAs whose expression is altered in cancer. Two gene clusters 
located at different chromosomes code for miR-200a/miR-200b/miR-429 (at chr1p36) and for miR-200c/miR-141 
(at chr12p13). miR-200b, miR-200c and miR-429 share an almost identical seed sequence “AAU ACU G”, while 
the seed of miR-200a and miR-141 differentiates from the other members for only one nucleotide “AAC ACU 
G”1. The expression regulation of the miR-200 family was associated with the i) suppression of EMT and tumor 
metastases through the miR-200/ZEB1-2  axis2, ii) inhibition of cancer stem cell self-renewal and  differentiation3, 
and iii) reversal of  chemoresistance4. Despite comprehensive literature that largely described the molecular 
function of miR-200 family, the precise role of these miRNAs in cancer has not yet completely understood, with 
some reports suggesting more prevalent oncosuppressive roles while other studies some possible oncogenic 
functions. Similar inconsistencies are also evident in few studies evaluating miR-200 family expression in tissues 
and their potential role as prognostic  biomarkers5. For example, low miR-200b/c expression in breast cancer 
was correlated with  death3–5, whereas high miR-200a expression was correlated with the development of distant 
 metastases6. By comparing miRNA expression in normal breast tissue, in situ carcinoma, non-metastatic and 
metastatic breast cancers, Sánchez-Cid et al. also found that miR-200a/b were increased in metastatic tumors as 
compared to non-metastatic  cancer7.
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These contrasting results led us to perform an extensive expression analysis of the entire miR-200 family in 
two large cohorts of breast cancer patients, the first collected in our hospital (H-CSS cohort, N = 283) and the 
second from The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA cohort, N = 451), in order 
to clarify the extent of miR-200 family deregulation in breast cancer, and its specific association with clinico-
pathological parameters.
Results
Patients and treatment. Table  1 summarizes the clinicopathological information obtained from the 
review of medical records and descriptive statistics for the 287 enrolled cases (H-CSS cohort). Metastases at 
diagnosis were present in 16 cases; among non-metastatic patients (N = 271), 55 experienced disease progres-
sion (Incidence Rate, IR of 3.5 events per 100 person-years), and 30 of them died for the disease (IR of 1.7 
events per 100 person-years). The median time to disease progression was 69.8  months (IQR: 33.8–107.5), 
whereas the overall follow-up time was 75.1  months (IQR: 40.6–109.7). Hormone receptor positive breast 
Table 1.  Clinicopathological characteristics of the H-CSS patient cohort (N = 287).
Variable Category
Age (years)
Mean ± SD 59.02 ± 13.60
Median (IQR) 59.68 (47.39–70.54)
Range 29.7–89.3
Tumor dimension (cm)
Mean ± SD 2.97 ± 1.65
Median (IQR) 2.5 (2.0–3.5)
Range 0.5–11
Ki67
Mean ± SD 35.69 ± 23.16

















Stage I 43 (14.98)
Stage IIa 99 (34.49)
Stage IIb 45 (15.68)
Stage IIIa 22 (7.67)
Stage IIIb 30 (10.45)
Stage IIIc 32 (11.15)



















Luminal A-like 104 (38.24)
Luminal B-like 96 (35.29)
Triple Negative 38 (13.97)
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tumors were defined as cases expressing estrogen (ER) or progesterone (PgR) receptors in ≥ 1% of neoplastic 
cells as indicated by international  guidelines8, and HER2 status assessment was carried out according to standard 
 recommendations9. Cases were staged according to the World Health Organization staging system version  7th10. 
The surrogate molecular classification was performed as described by Pasculli et al.11. Overall, 104 cases (38%) 
were classified as Luminal A, 96 cases (35%) as Luminal B; 34 cases (12%) were HER2-amplified, and 38 cases 
(14%) were Triple Negative (Table 1). Fifteen cases were not classified because the HER2 and or ki67 status was 
not reported in the medical records. All patients received breast-conserving surgery or total mastectomy, plus 
sentinel node biopsy or complete axillary dissection. Post-surgery treatments were performed according to the 
following guidelines: San Gallen, NCCN and ASCO. Recurrence was defined as evidence of loco-regional and/
or distant disease over 4 months from diagnosis and after curative-intent surgical treatment.
Selection of TCGA‑BReast invasive CAncer (TCGA‑BRCA) cohorts. We selected a cohort of 1053 
women with breast cancer not treated with neoadjuvant therapy from the TCGA data portal (https ://porta l.gdc.
cance r.gov/). All tumors had available expression profile for all the five miRNAs of the miR-200 family. The 
log2 read counts were used for miRNA expression analysis. The TCGA-BRCA cohort was harmonized with the 
H-CSS cohort by using a two-step approach (Supplemental Fig. 2 and Supplemental Table 1): (i) the TCGA-
BRCA cohort was limited to those histotypes (NST and ILC) and stages (I-IIa/b, IIIa/c and IV) represented in 
H-CSS (N = 822); (ii) we performed a random disproportionate sampling to align the distribution of histotypes 
and stages between the two cohorts; weights were overall based on H-CSS distribution, with the exception that 
we reduced the weights for late stages not to deplete the final cohort’s size extensively. We ultimately selected 
451 patients for all subsequent analyses. Characteristics of these cohorts are reported in Supplemental Table 1.
Analysis of variance, run through a general linear model, was performed to evaluate the association of 
miRNAs expression and clinicopathological features, considering both main effects and interaction terms. Cox 
regression model was implemented to estimate hazard ratios for overall survival, defined as the time from the 
date of tumor resection until death from any cause. We also downloaded miRNA expression data for 104 avail-
able normal breast tissues from TCGA-BRCA data portal. Forty-eight of these normal samples were matched to 
48 tumor counterparts among the cohort of 451 women considered.
miR‑200 family expression in tumor samples as compared with normal tissues. Following eval-
uation of RNA quality, 283 out of the 287 samples from the H-CSS cohort showing an RNA Integrity Number 
(RIN) > 7.0 were suitable for the analysis (Supplemental Fig. 1). Thus, the expression profile of the entire miR-200 
family could be performed in 283 breast cancers, and in 13 normal breast tissues (NBTs) obtained from reduc-
tive mammoplasty. As shown in Supplemental Table 2A and Fig. 1, all miRNAs were significantly overexpressed 
in tumors (p < 0.001) when compared to NBTs. Furthermore, almost all miR-200 family members (except for 
miR-200b-3p) were overexpressed in tumors as compared to normal tissue adjacent to tumor (Margin) (Sup-
plemental Table 2B). Accordingly, in the TCGA-BRCA cohort, we confirmed the overexpression of miR-200 
family in breast tumors vs. normal breast tissues (p < 0.0001) (Supplemental Table 3A and Fig. 2) and in matched 
tumor-normal pairs (N = 48; Supplemental Table 3B).
Association among miR‑200 family expression and tumor clinicopathological features. Next, 
we analyzed the correlation of miR-200 family expression with the clinicopathological characteristics in both the 
H-CSS (Table 2) and TCGA-BRCA cohorts (Supplemental Table 4A). In the H-CSS cohort (Table 2), the analysis 
across breast cancer (BC) molecular subtypes (Luminal A, Luminal B, HER2-amplified, and basal/Triple-negative 
(TNEG); see “Methods”) showed a lower expression of miR-141-3p (p = 0.0306) and miR-200a-3p (p = 0.0381) 
in those tumors associated to more aggressive subtypes (e.g. LUMB, HER2-amplified and TNEG) Table 2). In 
particular, miR-141-3p was less expressed in HER2-amplified and TNEG tumors, while miR-200a-3p was less 
expressed in HER2-amplified, Luminal B and TNEG subtypes (Fig. 3). Consistently, in the TCGA-BRCA cohort, 
we found that miR-141-3p was downregulated in the Normal-like subgroup (p = 0.0210) while miR-200a-3p was 
downregulated in HER2-amplified and Luminal B tumors (p = 0.0200). In addition, miR-200b-3p was found 
down regulated in the HER2-amplified subgroup (p = 0.0060) (Supplemental Table 4A; Fig. 4).
In the H-CSS cohort, miR-141-3p, miR-200a-3p and miR-429 expression was increased in advanced stage 
disease (stage IV) (p = 0.037, p = 0.0011 and p = 0.0078 respectively) (Table 2). In the TCGA cohort, miR-200a-3p 
(p = 0.0128), miR-200b-3p (p = 0.0009) and miR-200c-3p (p = 0.0013) were increased in invasive lobular carci-
noma (Supplemental Table 4A). To evaluate whether these differences may affect the association with molecular 
subtypes, we performed a multivariable analysis adjusting for stage, histotype and molecular subtype. Overall, our 
results indicate that miR-200a-3p and miR-141-3p remain significantly associated with the molecular subtypes 
in breast cancer after the adjustments in the H-CSS cohort (Table 3), whereas an association with miR-141-3p 
and miR-200c-3p was found in the TCGA cohort (Supplemental Table 4B).
Evaluation of miR‑200 family prognostic value in breast cancer cases. The association with time-
to-event outcomes (i.e. CSS, DFS, and MFS) was evaluated in the H-CSS cohort without metastases at diagno-
sis and with complete information about survival outcomes (Supplemental Fig. 1). As shown in Supplemental 
Tables 5 and 6, tumor dimension, stage, hormone receptor status, HER2-amplification, and surrogate molecular 
classification were associated with DFS, MFS, and CSS, while high Ki67 was associated with DFS and MFS only. 
No statistically significant associations were found with any miRNA of miR-200 family in the overall population. 
Next, we investigated the prognostic role of the miR-200 family in the TCGA-BRCA cohort by considering the 
subgroup of patients without metastases at diagnosis (cohort C1, N = 435; Supplemental Fig. 2). We scored 56 
deaths and a median follow-up for surviving women of 2.4 years (Q1 = 1.2; Q3 = 4.6 years). Although this cohort 
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showed a shorter follow-up and limited number of events, we were able to confirm the prognostic role of stage, 
estrogen and progesterone receptor status, HER2 status, and molecular subtypes (Supplemental Table 7A). In 
line with the results obtained in the H-CSS, we did not observe a statistically significant association of any of 
the miR-200 family members with overall survival (OS) in multivariate analysis (Supplemental Table 7B). These 
figures were confirmed in the larger cohort of N = 806 subjects without metastases (cohort B1, Supplemental 
Fig. 2), scoring 101 events, and with a follow-up length (median = 2.4 years; Q1 = 1.2; Q3 = 4.7) comparable to 
the smaller C1 cohort (Supplemental Table 7A, B).
Last, we evaluated whether the combined expression of miR-200 family members was able to predict survival 
outcomes. As shown in Table 4, when all miRNAs were jointly considered for the building of the weighted scores, 
only a slight predictive accuracy on H-CSS outcome at 12 years was found (survival c-statistic: 0.646; 95%CI 
0.538–0.754). Regression coefficients (weights) used to calculate the scores were reported in Table 5.
Discussion
In the attempt to elucidate the extent of miR-200 family deregulation in breast cancer and, hence, its potentiality 
as clinically significant biomarker, we profiled a large series of breast cancer cases with a long follow-up (H-CSS 
cohort) and the TCGA-BRCA cohorts. First, we found in both H-CSS and TCGA-BRCA cohorts that the global 
miR-200 family expression is increased in tumors as compared with normal breast tissue or margin. Since miR-
200 family is mainly expressed in epithelial cells, these results are most likely due to the enrichment in fibrous 
connective adipose tissue typical of the normal breast. The enrichment in normal breast epithelial component 
might also explain some inconsistencies among literature data. Consistently with our data, Amorim et al.12 found 
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Figure 1.  miR-200 family members expression in H-CSS cohort in tumor tissues (T), normal breast tissues 
distant from tumor (M) and normal breast tissue from reductive mammoplasty (NBT). Plots were performed 
using the R Foundation for Statistical Computing (version 3.6, packages: ggplot2, gridExtra).
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an increased expression of miR-200b-3p and miR-141-3p in tumors as compared with margin, whereas other 
studies reported reduced expression of miR-200b-3p3 and miR-200c-3p5 in tumors as compared with margins.
In both H-CSS and TCGA-BRCA cohorts, we found a differential expression of miR-200 family members 
within the molecular subgroups identified by the surrogate molecular classification (H-CSS cohort) and intrinsic 
molecular subtypes (TCGA-BRCA cohort). In particular, lower expression of miR-141-3p/miR-200a-3p was 
associated with HER2-amplified, Luminal B, and Triple Negative (H-CSS cohort) or Normal Like (TCGA-BRCA 
cohort) breast cancer subtypes. This is consistent with reports describing that miR-200 family loss of expression 
unleashes ZEB1  expression13, which in turn induces epithelial-to-mesenchymal transition (EMT), which is an 
important step forward in the initial phase of the metastatic spreading from the primary tumor.
Functionally speaking, the association between miR-200 family and metastatic processes have been widely 
investigated in different tumor types, including breast cancer and, once again, conflicting results have been 
reported. Indeed, the ectopic expression of miR-200a and miR-200b was shown to inhibit EMT features in 
undifferentiated, non-tumorigenic breast cancer cells, and impair proliferation, migration, and invasion in triple 
negative breast  cancer14. Accordingly, miR-200c/141 cluster deletion affects breast cancer stem cell heterogeneity 
by promoting the generation of EMT-like stem cells, which resulted in increased tumor  metastasis3. miR-200 
family members were also found to support Epidermal Growth Factor (EGF)-driven invasion, with the miR-
200bc/429 cluster showing stronger effects than the miR-200a/141  cluster1,15. Moreover, miR-200a suppressed 
cell proliferation in breast cancer by targeting mitochondrial transcription factor  A16, and impaired EMT-like 
transformation, thus migration, by regulating SIRT1 in breast epithelial  cells17. Nevertheless, while these stud-
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Figure 2.  miR-200 family members expression in TCGA-BRCA cohort in tumor tissues (T), and normal breast 
tissues distant from tumor (N). Plots were performed using the R Foundation for Statistical Computing (version 
3.6, packages: ggplot2, gridExtra).
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miRNA Clinical variable Category N Statistic# p value*
miR-141-3p
Age –- 283 r = 0.016 0.7948
Tumor dimension –- 283 r = 0.035 0.5616
Ki67 –- 263 r =  − 0.128 0.0379
Menopause
No 85 38.61 (26.49–76.48)
0.0961
Yes 198 53.51 (25.9–93.03)
Tumor Histotype
NST 257 50.63 (27.35–81.07)
0.7499NST + ILC 5 34.39 (28.98–48.48)
ILC 21 56.83 (20.8–109.97)
Site
Bilateral 2 98.04 (56.14–139.94)
0.4226Right 134 49.71 (26.49–89.27)
Left 147 52.02 (25.9–78.94)
Estrogen receptor
Negative 69 36.69 (20.98–65.17 )
0.0146
Positive 214 53.84 (28.01–93.37 )
Progesterone reeceptor
Negative 85 37.95 (24.14–65.88 )
0.0352
Positive 198 54.05 (28.05–94.51 )
Her2neu
Amplified 64 44.64 (26.2–72.35 )
0.1379
Negative 212 52.98 (27.05–91.71 )
Stage (WHO 7)
Stage I 41 57.35 (39.33–88.36)
0.0370
Stage IIa 98 42.55 (23.1–78.4)
Stage IIb 45 50.77 (28.05–65.08)
Stage IIIa 22 43.66 (17.62–54.23)
Stage IIIb 30 65.2 (28.74–128.88)
Stage IIIc 31 45.74 (24.65–80.52)
Stage IV 16 80.58 (29.82–189.07)
Histological grade
1 26 47.56 (28.74–103.33)
0.14012 124 53.66 (28.52–97.22)
3 103 38.61 (23.1–72.73)
Surrogate molecular classification
HER2 amplified 33 31.94 (18.63–51.91)
0.0306
Luminal A 104 56.99 (28.4–105.55)
Luminal B 93 53.51 (27.72–87.22)
Triple Negative 38 38.32 (26.74–73.94)
hsa-miR-200a
Age –- 283 0.028 0.6335
Tumor dimension –- 283 0.005 0.9334
Ki67 –- 263  − 0.105 0.0893
Menopause
No 85 43.13 (24.73–75.42)
0.2043
Yes 198 50.8 (24.68–90.39)
Tumor Histotype
NST 257 48.76 (25.46–84.75)
0.5089NST + ILC 5 35.79 (25.72–36.42)
ILC 21 44.65 (19.03–166.08)
Site
Bilateral 2 147.61 (94.3–200.92)
0.3743Right 134 42.36 (25.72–76.84)
Left 147 53.33 (23.69–86.71)
Estrogen receptor
Negative 69 33.37 (21.48–78.68 )
0.2981
Positive 214 51.77 (26.26–86.71 )
Progesterone receptor
Negative 85 44.17 (23.02–76.59 )
0.4315
Positive 198 51.02 (26.36–90.39 )
Her2neu
Amplified 64 40.18 (23.21–69.3 )
0.1009
Negative 212 52.97 (24.7–95.68 )
Stage (WHO 7)
Stage I 41 44.93 (23.02–85.32)
0.0011
Stage IIa 98 36.49 (20.96–67.7)
Stage IIb 45 55.65 (28.99–85.68)
Stage IIIa 22 38.81 (21.48–78.68)
Stage IIIb 30 56.9 (33.36–161)
Stage IIIc 31 44.17 (27.28–80.1)
Stage IV 16 105.65 (36.9–204.02)
Histological grade
1 26 58.14 (25.72–96.78)
0.28942 124 52.57 (26.27–87.14)
3 103 43.13 (19.23–67.7)
Surrogate molecular classification
HER2 amplified 33 33.37 (18.44–55.43)
0.0381
Luminal A 104 58.18 (26.86–97.92)
Luminal B 93 41.71 (26.19–73.5)
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miRNA Clinical variable Category N Statistic# p value*
hsa-miR-200b
Age –- 283  − 0.031 0.6072
Tumor dimension –- 283 0.039 0.5088
Ki67 –- 263  − 0.095 0.1226
Menopause
No 85 196.75 (116.38–279.00)
0.7207
Yes 198 200.15 (112.31–301.69)
Tumor histotype
NST 257 197.42 (111.71–289.32)
0.4229NST + ILC 5 222.86 (175.98–233.38)
ILC 21 219.44 (119.66–569.52)
Site
Bilateral 2 242.05 (204.54–279.55)
0.7886Right 134 190.94 (106.23–273.31)
Left 147 201.83 (126.28–330.57)
Estrogen receptor
Negative 69 178.88 (119.12–266 )
0.5246
Positive 214 203.34 (111.71–319.75 )
Progesterone receptor
Negative 85 178.88 (113.62–264.23 )
0.5849
Positive 198 204.09 (112.31–323.37 )
Her2neu
Amplified 64 199.09 (115.02–273.7 )
0.3643
Negative 212 200.37 (113.41–307.4 )
Stage (WHO 7)
Stage I 41 182.02 (119.66–279)
0.0684
Stage IIa 98 188.17 (108.48–268.28)
Stage IIb 45 248.55 (135.31–330.57)
Stage IIIa 22 177.43 (75.74–365.43)
Stage IIIb 30 224.37 (142.77–476.98)
Stage IIIc 31 203.04 (113.62–267.86)
Stage IV 16 235.35 (134.93–511.01)
Histological grade
1 26 180.52 (91.35–301.69)
0.59032 124 202.44 (110.15–338.3)
3 103 194.95 (113.2–264.23)
Surrogate molecular classification
HER2 amplified 33 176.36 (126.28–242.73)
0.1588
Luminal A 104 224.15 (120.3–352.84)
Luminal B 93 197.15 (101.09–285.24)
Triple Negative 38 199.11 (123.11–272.04)
hsa-miR-200c
Age –- 283  − 0.033 0.5780
Tumor dimension –- 283 0.044 0.4606
Ki67 –- 263  − 0.068 0.2738
Menopause
No 85 781.21 (572.53–1125)
0.5383
Yes 198 814.66 (534.54–1237.5)
Tumor histotype
NST 257 793.15 (556.83–1191.88)
0.6936NST + ILC 5 786.62 (768.82–1068.29)
ILC 21 992.52 (542.84–1486.69)
Site
Bilateral 2 1831.45 (1475.34–2187.57)
0.3406Right 134 790.84 (522.03–1216.31)
Left 147 794.84 (562.58–1191.88)
Estrogen receptor
Negative 69 781.21 (452.92–1194.55 )
0.6537
Positive 214 804.54 (561.25–1216.31 )
Progesterone receptor
Negative 85 768.82 (452.92–1194.55 )
0.6473
Positive 198 808.92 (572.53–1210.46 )
Her2neu
Amplified 64 881.74 (604.47–1286.37 )
0.9829
Negative 212 787.79 (550.85–1187.66 )
Stage (WHO 7)
Stage I 41 744.36 (576.41–1119.53)
0.2718
Stage IIa 98 791.57 (528.96–1232.86)
Stage IIb 45 867.48 (626.76–1227)
Stage IIIa 22 796.29 (420.18–1128.67)
Stage IIIb 30 878.03 (595.54–1411.15)
Stage IIIc 31 773.83 (562.58–1092.21)
Stage IV 16 787.49 (527.48–1355.04)
Histological grade
1 26 667.19 (488.12–1097.21)
0.43652 124 805.55 (572.36–1167.01)
3 103 812.15 (574.36–1229.08)
Surrogate molecular classification
HER2 amplified 33 791.69 (497.88–1194.55)
0.5229
Luminal A 104 811.76 (582.91–1229.93)
Luminal B 93 836.18 (595.54–1175.58)
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of miR-200 family members might induce rather than prevent metastases formation. For instance, the forced 
expression of miR-200a/miR-200b in MCF10 mammary cells induced an enhanced epithelial program, aldehyde 
dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures 
while promoting orthotopic tumor growth and lung colonization in vivo, suggesting that miR-200 family mem-
bers may promote traits of highly proliferative breast luminal progenitor  cells7. Likewise, miR-200c/141 cluster 
overexpression induced by SerpinB2 was shown to foster breast cancer cell  metastasis18. Furthermore, miR-200a 
overexpression was found to enhance malignant transformation of immortalized human mammary epithelial 
 cells19, to protect tumor cells from apoptosis, and promote  metastases4 and  chemoresistance20. Altogether, these 
discrepancies lead to hypothesize that the biological functions of miR-200 family members may depend on the 
cellular context, tumor molecular subtype, and stage of tumor  progression21.
In our study, the association between miR-200 family expression and patients’ outcome was evaluated in 
terms of DFS, MFS, and CSS in the H-CSS cohort including 283 non-metastatic breast cancer cases with a 
median follow-up of 75 months. In the TCGA-BRCA cohort, only overall survival data were available instead. 
Our analyses did confirm the prognostic role of lymph node status, estrogen and progesterone receptors status, 
HER2 status, and molecular subtypes in both H-CSS and TCGA-BRCA cohorts. However, we did not observe 
any statistically significant association of the miR-200 family members with patients’ outcome in multivariable 
analyses. Indeed, in the H-CSS cohort, the combined expression of miR-200 family members only showed a 
slight predictive accuracy on CSS outcome at 12 years (Table 4).
To date, only a minority of  studies22 have performed the expression analysis of miR-200 family members in 
breast cancer tissues, and evaluated its association with patients’ outcomes (Fig. 5, and Supplemental Table S8). 
Among those, only one study reported an hazard ratio of 0.231 (95%CI 0.094–0.564) in univariable analysis for 
miR-200c in a patient cohort including only luminal  tumors12. Other three  studies23–25 evaluated the association 
between miR-200 family members expression in plasma samples and patient’s outcome (Supplemental Table S8). 
miRNA Clinical variable Category N Statistic# p value*
hsa-miR-429
Age –- 282  − 0.05 0.4004
Tumor dimension –- 282 0.046 0.4451
Ki67 –- 262  − 0.049 0.4313
Menopause
No 85 47.03 (28.57–75.29)
0.6537
Yes 198 49.1 (24.94–99.57)
Tumor histotype
NST 257 47.03 (25.41–91.93)
0.4162NST + ILC 5 48.48 (45.43–87.35)
ILC 21 55.37 (19.03–108.22)
Site
Bilateral 2 89.15 (15.14–163.17)
0.9737Right 134 44.61 (24.94–87.71)
Left 147 50.75 (25.44–99.57)
Estrogen receptor
Negative 69 46.69 (22.94–87.71 )
0.4817
Positive 214 49.6 (26.91–93.37 )
Progesterone receptor
Negative 85 46.26 (23.28–87.71 )
0.4184
Positive 198 49.97 (27.2–99.57 )
Her2neu
Amplified 64 44.54 (26.16–84.92 )
0.2805
Negative 212 50.42 (25.42–102.58 )
Stage (WHO 7)
Stage I 41 48.48 (22.94–83.93)
0.0078
Stage IIa 98 41.94 (22.92–66.79)
Stage IIb 45 58.16 (32.02–90.82)
Stage IIIa 22 46.48 (28.81–136.24)
Stage IIIb 30 77.09 (37.76–152.36)
Stage IIIc 31 42.25 (28.57–76.99)
Stage IV 16 97.96 (37.67–169.11)
Histological grade
1 26 48.99 (23.28–104.25)
0.21332 124 49.97 (26.34–101.45)
3 103 44.39 (25.41–74.27)
Surrogate molecular classification
HER2 amplified 33 43.79 (23.52–56.63)
0.4289
Luminal A 104 50.68 (26.34–106.23)
Luminal B 93 45.73 (24.94–85.39)
Triple negative 38 53.89 (25.41–117.92)
Table 2.  Association between miRNAs and clinicopathological variables. # In case of continuous clinical 
variables (i.e. age, tumour dimension and Ki67), r denotes Pearson correlation coefficient with log-transformed 
miRNA expression whereas in presence of categorical clinical variables, median along with interquartile range 
(IQR, i.e. first-third quartiles) of the miRNA expression was reported. *p values from Pearson correlation or 
two-sample t test (or ANOVA model as appropriate) using log-transformed miRNA expressions was reported 
for continuous and categorical variables, respectively. p-value <0.05 are reported in bold.
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In particular, Medhavan et al.24 found an association between increased expression of miR-200a, miR-200b and 
miR-200c and higher risk of overall mortality in univariable analyses (Fig. 5).
Conclusion
To the best of our knowledge, this is the first study evaluating the expression of all miR-200 family members 
in breast cancer tissues in order to identify potential combination biomarkers of clinical relevance. Our results 
suggest a differential expression of miR-200 family in breast cancer as compared to normal breast, and within 
the breast cancer molecular subgroups identified by either surrogate classification (H-CSS cohort) or intrinsic 
molecular classification (TCGA-BRCA cohort). Nevertheless, the correlation analyses with breast cancer patients’ 
prognosis exclusively found a weak predictive accuracy of the combined expression of miR-200 family on CSS 
outcome at 12 years in the H-CSS cohort. Although these results seem not to encourage the use of miR-200 
family members as combination biomarkers in breast cancer, we cannot rule out that such a role might be held 
within a single breast cancer subgroup. Indeed, in the H-CSS cohort the number of cases and event outcome 
is not sufficient for subgroup analyses, whereas only partial information about overall survival and no data on 
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Figure 3.  miR-200 family members expression within the surrogate molecular classification subgroups 
identified in the H-CSS cohort: HER2 amplified tumors (HER2), Luminal A (LUMA), Luminal B (LUMB), 



































































































Figure 4.  miR-200 family members differential expression within the intrinsic molecular classification 
subgroups in the TCGA-BRCA cohort: HER2 enriched tumors (HER2), Luminal A (LUMA), Luminal B 
(LUMB), Basal like, and NORMAL LIKE tumors. Plots were performed using the R Foundation for Statistical 
Computing (version 3.6, packages: ggplot2, gridExtra).
Table 3.  Univariate and multivariable analysis of the association between miRNAs and clinicopathological 
characteristics in the TCGA cohort. *p-values <0.05 are reported in bold.
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progression are available within the TCGA-BRCA cohort. Thus, this possibility needs to be further investigated 
in studies specifically designed to evaluate miR-200 family expression in each of the breast cancer subtypes.
Materials and methods
Study design, setting and eligibility criteria. This study is part of the project TRANSCAN Joint Trans-
national Call (JTC) 2013-BREMIR initiated in 2015 at the Fondazione IRCCS Casa Sollievo della Sofferenza 
(H-CSS), aimed to identify novel biomarkers predicting disease progression and metastases development in 
breast cancer patients. In this study, we evaluated the miR-200 family expression in a retrospective consecutively 
collected cohort of 287 breast cancer cases (H-CSS cohort) with a median age of 60 years (Supplemental Table 1).
We conducted the study according to the REporting of tumor MARKer Studies (REMARK)  guidelines8,26, 
and a prospectively written research (TRANSCAN-BREMIR) plan. Breast cancer tissues were collected between 
January 2006 and December 2014 at the Breast-Unit, Fondazione IRCCS Casa Sollievo della Sofferenza.
Following pathological evaluation, tissue samples were snap-frozen in liquid nitrogen and stored at − 80 °C. 
For legal reasons, only women older than 18 years of age with tumors greater than 1.0 cm in diameter were 
included in the study. For each sample, a 5 μm hematoxylin/eosin stained section was visually inspected by light 
microscopy to select tumor areas with at least 70% viable cancer cells rather than normal specimens, obtained 
from reductive mammoplasty, to check for the absence of tumor cells among normal epithelial. The study meth-
odologies using these samples were carried out following the international of Helsinki Declaration 7th revision 
(2013, EU Directive 2004/23/EC) and the Italian (D. Lgs. 30/06/2003, n. 196) regulations for research on human 
subjects. All experimental procedures of this study were approved by the Ethical Committee of the Fondazione 
IRCCS Casa Sollievo della Sofferenza (Prot N 140/CE). A written informed consent was obtained from all patients 
following the experimental protocol approved by the Ethical Committee.
RNA isolation and RT‑qPCR analysis. RNA was isolated from H-CSS tissue samples by Trizol reagent 
(Invitrogen) according to the manufacturer’s instructions. Total RNA concentration was determined by the 
absorbance measurement at 260 nm and 280 nm using the NanoDropTM 1000 spectrophotometer (Thermo 
Fisher Scientific). The RNA quality and integrity were analyzed through 2100 Expert Analyzer (Agilent Technol-
ogy), and only RNAs with RIN (RNA Integrity Number) ≥ 7.0 were considered acceptable. Then, 10 ng of total 
RNA was reverse transcribed to single stranded cDNA by using TaqMan MicroRNA Reverse Transcription Kit 
Table 4.  Prognostic accuracy of each outcome-specific weighted miRNA score at median and maximum time 
horizons. *95% confidence interval after 1000 perturbation-resamplings of the data.
Outcome Time horizon (years) N.events/total Survival c-statistic (95%CI*)
Cancer specific survival (CSS)
7 (median) 27/263 0.650 (0.535–0.766)
12 (max) 29/263 0.646 (0.538–0.754)
Progression free survival (PFS)
7 (median) 45/263 0.590 (0.497–0.682)
12 (max) 53/263 0.528 (0.402–0.654)
Distant metastases free survival (MFS)
7 (median) 43/259 0.613 (0.527–0.699)
12 (max) 52/258 0.572 (0.479–0.664)
Table 5.  Estimated regression coefficients used to compute multiple weighted miRNA scores.
Outcome miRNA (log expressions) coefficients (weights) p value
Cancer specific survival (csS)
hsa-miR-141  − 0.77834 0.0073
hsa-miR-200a 0.77455 0.0495
hsa-miR-200b  − 1.22087 0.0433
hsa-miR-200c 0.71390 0.1173
hsa-miR-429 0.23035 0.4661
Progression free survival (pfs)
hsa-miR-141  − 0.50129 0.0170
hsa-miR-200a 0.57881 0.0540
hsa-miR-200b  − 0.78914 0.0730
hsa-miR-200c 0.48904 0.1450
hsa-miR-429 0.09213 0.6720
Distant metastases free survival (mfs)
hsa-miR-141  − 0.52081 0.0110
hsa-miR-200a 0.44872 0.1270
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(Thermo Fisher Scientific) and 5 × specific stem-loop RT primers for both individual miR-200 family members 
and the endogenous control, according to the manufacturer’s instructions. RT positive and negative controls 
were included in each batch of reactions. To assess miR-200 family expression levels in the H-CSS cohort, we 
applied a relative quantification method with a standard  curve27. The expression levels of each miR-200 fam-
ily member were assessed by using TaqMan MicroRNA Assays that were as follows: hsa-miR-200a-3p, assay 
ID: 000502; hsa-miR-200b-3p, assay ID: 002251; hsa-miR-200c-3p, assay ID: 002300; hsa-miR-141-3p, assay 
ID: 000463; hsa-miR-429, assay ID: 001024, and normalized to RNU48 endogenous control, assay ID: 001006 
(Thermo Fisher Scientific).
Each qPCR run was performed by using 0.5 μl of TaqMan microRNA (20X), 5 μl of TaqMan Universal PCR 
Master Mix II, No AmpErase UNG, and 1 μl of cDNA. The PCR conditions were as follows: at 95 °C for 10 min, 
followed by 40 cycles (95 °C for 15 s, 60 °C for 1 min). All samples were run in triplicates. Each plate included 
positive and negative controls of reverse transcription and multiple water blanks. qPCR reactions were per-
formed on ABI PRISM 7900HT Sequence Detection System and the SDS 2.4 software (Thermo Fisher Scientific) 
was used for post-run analyses. For each miR-200 family member and RNU48 control, standard curves were 
Figure 5.  Forest plot of hazard ratios (HR) for studies on plasma samples from breast cancer patients. Plots 
were performed using the R Foundation for Statistical Computing (version 3.6, packages: ggplot2, gridExtra).
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constructed by plotting the threshold cycle (Ct) values against log10 of the copy number, and fitting by linear 
least square regression. For each sample, miR-200 family member expression was determined as the ratio of any 
single miR-200 family member’s copy number to the RNU48 copy number. Then, it was multiplied by 1000 for 
more straightforward tabulation (i.e. miRNA target/RNU48) × 1000)27.
Statistical analysis. Patients’ clinicopathological characteristics were reported as median along with inter-
quartile range (IQR, i.e. first-third quartiles) or frequencies and percentages for continuous and categorical 
variables, respectively. Normal distribution assumption of miRNA expression was evaluated by Q-Q plots and 
Shapiro-Wilks test, and a log-normal distribution for all miR-200 family members was detected. The two-sample 
t test (or ANOVA model as appropriate) was used to assess comparisons of log-transformed miRNA expression 
among patient groups. Pearson correlation coefficient was estimated to assess the correlation between natural 
log of miRNA expression and continuous variables. Time-to-event analyses were performed by univariable and 
multivariable proportional hazards Cox regression models and risks were reported as Hazard Ratios (HR) along 
with their 95% Confidence Interval (95%CI).
The individual overall follow-up time was defined as the time between the enrollment date (i.e. at the time 
of snap-frozen fresh tissue collection) and the occurrence of the death due to cancer (Cancer Specific Survival, 
CSS), whereas the individual time to tumor progression or distant metastasis was defined as the time between 
the enrollment date and the occurrence of the first disease progression (Disease Free Survival, DFS), or the first 
distant metastasis (Metastasis Free Survival, MFS). For patients who did not experience any event as above, their 
individual follow-up time was defined as the time between the enrollment date and the end of the observational 
period (i.e. last available examination).
Furthermore, annual mortality and disease progression rates were defined as the number of events divided 
by the number of person-years × 100. When each miRNA expression was considered as the main covariate into 
a univariable Cox model, HRs were reported with respect to patients groups defined by miRNA’s median value 
(i.e. above vs. below the median). Moreover, multivariable Cox models were also performed with the inclusion of 
lymph node and surrogate molecular classification as further covariates. A weighted miRNA score was computed 
for each survival outcome at issue by the assessment of a multivariable Cox model, which included all miRNAs 
(natural log of expression) of the miR-200 family as main covariates. Weighted scores were calculated as the 
linear combination of the regression coefficients by the value of each miRNA (natural log of expression). The 
prognostic accuracy of each miRNA score was assessed at 7 (i.e. the median time horizon) and at 12 years (i.e. 
the maximum time horizon) by survival C-statistic, along with its 95% CIs derived following 1000 perturbation-
resampling28. A two-sided p value < 0.05 was considered for statistical significance. All statistical analyses were 
performed using SAS Release 9.4 (SAS Institute, Cary, NC, USA). Plots were performed using the R Foundation 
for Statistical Computing (version 3.6, packages: ggplot2, gridExtra).
Ethics approval and consent to participate. The study methodologies using human samples were car-
ried out following the international of Helsinki Declaration 7th revision (2013, EU Directive 2004/23/EC) and 
the Italian (D. Lgs. 30/06/2003, n. 196) regulations for research on human subjects. All experimental procedures 
of this study were approved by the Ethical Committee of the IRCCS Casa Sollievo della Sofferenza (Prot N 140/
CE). The informed consent was obtained from all patients following the experimental protocol approved by the 
Ethical Committee.
Data availability
The datasets analysed during the current study are available from the corresponding author on reasonable request.
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